Winston Pharmaceuticals (Winston Pharmaceuticals) EBIT : $-2.42 Mil (TTM As of Mar. 2010)

View and export this data going back to 2006. Start your Free Trial

What is Winston Pharmaceuticals EBIT?

Winston Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2010 was $-0.46 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2010 was $-2.42 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Winston Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2010 was -977.78%. Winston Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2010 was -14,215.38%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Winston Pharmaceuticals EBIT Historical Data

The historical data trend for Winston Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Winston Pharmaceuticals EBIT Chart

Winston Pharmaceuticals Annual Data

Trend

Sep05

Sep06

Sep07

Dec08

Dec09

EBIT

-0.22

-0.43

-0.22

-5.23

-2.74

Winston Pharmaceuticals Quarterly Data
	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10
EBIT	Get a 7-Day Free Trial														-0.79	-0.69	-0.70	-0.56	-0.46

Competitive Comparison of Winston Pharmaceuticals's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Winston Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Winston Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Winston Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Winston Pharmaceuticals's EV-to-EBIT falls into.

Winston Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2010 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.42 Mil.

Winston Pharmaceuticals (GREY:WPHM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Winston Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2010 is calculated as:

	ROC % (Q: Mar. 2010 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2009 )	+	Invested Capital (Q: Mar. 2010 ))	/ count )
=	-1.848 * ( 1 - 0% )	/	( (0.347	+	0.031)	/ 2 )
=	-1.848	/	0.189
=	-977.78 %

where

	Invested Capital		(Q: Dec. 2009 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.676	-	0.871	-	( 1.563	-	max(0, 1.187	-	1.645	+	1.563	))
=	0.347

	Invested Capital		(Q: Mar. 2010 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.842	-	0.777	-	( 0.678	-	max(0, 0.777	-	0.811	+	0.678	))
=	0.031

Note: The Operating Income data used here is four times the quarterly (Mar. 2010) data.

2. Joel Greenblatt's definition of Return on Capital:

Winston Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2010 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2010 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2009		Q: Mar. 2010
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.848	/	( ( (0.014 + max(-1.127, 0))	+	(0.012 + max(-0.644, 0)) )	/	2 )
=	-1.848	/	( ( 0.014	+	0.012 )	/	2 )
=	-1.848	/	0.013
=	-14,215.38 %

where Working Capital is:

	Working Capital		(Q: Dec. 2009 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.016	+	0	+	0.044)	-	(0.871	+	0.317	+	-0.00099999999999989)
=	-1.127

	Working Capital		(Q: Mar. 2010 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.029	+	0.104)	-	(0.777	+	0	+	0)
=	-0.644

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2010) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Winston Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2010 )
	=	-2.415	/	0.000
	=	%

Winston Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Winston Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Winston Pharmaceuticals (Winston Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Winston Pharmaceuticals Inc (GREY:WPHM) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 North Fairway Drive, Suite 134, Vernon Hills, IL, USA, 60061

Website

http://www.winstonlabs.com

Winston Pharmaceuticals Inc is a pharmaceutical company, which is engaged in the discovery and development of products for pain management. The company focuses on major pain indications such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo- and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease.

Executives

Frost Phillip Md Et Al	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Frost Gamma Investments Trust	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137
Subbarao V Uppaluri	director	4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137
Curtis Lockshin	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Glenn L Halpryn	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Steven Jerry Glauser	10 percent owner	1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Noah M Silver	director, officer: Vice President	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Alan Jay Weisberg	director, officer: Chief Financial Officer	2500 NORTH MILITARY TRAIL, SUITE 206, BOCA RATON FL 33431
Stephen Bittel	10 percent owner	4400 BISCAYNE BOULEVARD SUITE 950 MIAMI FL 33137

Winston Pharmaceuticals (Winston Pharmaceuticals) Headlines

No Headlines